Valneva (NASDAQ:VALN) Upgraded to “Hold” by Zacks Investment Research

Valneva (NASDAQ:VALNGet Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Tuesday, Zacks.com reports.

According to Zacks, “Valneva SE is a specialty vaccine company. It is focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. Valneva SE is based in Saint-Herblain, France. “

Shares of NASDAQ VALN opened at $28.40 on Tuesday. Valneva has a 1 year low of $24.16 and a 1 year high of $67.84. The company has a quick ratio of 1.25, a current ratio of 1.59 and a debt-to-equity ratio of 0.30. The business has a 50-day moving average of $34.43 and a two-hundred day moving average of $41.10.

Institutional investors have recently bought and sold shares of the company. Morgan Stanley purchased a new stake in Valneva during the 3rd quarter valued at approximately $97,000. Millennium Management LLC purchased a new stake in Valneva during the 2nd quarter valued at approximately $259,000. Granite Point Capital Management L.P. purchased a new stake in Valneva during the 3rd quarter valued at approximately $376,000. Finally, Alps Advisors Inc. acquired a new position in Valneva during the 4th quarter worth approximately $3,369,000. 0.50% of the stock is owned by institutional investors and hedge funds.

Valneva Company Profile (Get Rating)

Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2.

Featured Stories

Get a free copy of the Zacks research report on Valneva (VALN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Valneva (NASDAQ:VALN)

Receive News & Ratings for Valneva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valneva and related companies with MarketBeat.com's FREE daily email newsletter.